ANTIDEPRESSANT THERAPY DURING PREGNANCY: AN INSIGHT ON ITS POTENTIAL HEALTHCARE COSTS
Main Article Content
Keywords
Pregnancy, antidepressants, costs, psychiatric disorders
Abstract
Background
Information on healthcare costs associated with poorly treated psychiatric disorders during and after pregnancy is limited.
Objective
To compare the direct healthcare costs, during and after pregnancy, between women who continue their antidepressant therapy during the whole gestational period and those who discontinue their treatment during the first trimester.
Methods
Data from a ‘Medications and Pregnancy’ registry were used. Eligible women were 1) aged 15 – 45, 2) insured by the Quebec drug plan for ?12 months prior to, during, and ?3 months after pregnancy, 3) had ?1 diagnoses of psychiatric disorders before pregnancy, 4) used antidepressants for ?30 days in the year before pregnancy, and 5) had delivered. Women who continued their antidepressant therapy throughout pregnancy (Group 1) were compared to those who discontinued during the first trimester (Group 2). Healthcare costs, expressed as mean total costs and cost ratios, were determined during and after pregnancy.
Results
In total, 2822 women met inclusion criteria. Of these, 501 (17.8%) were in Group 1, and 676 (23.4%) in Group 2. The median number of days of antidepressant use before pregnancy was higher in Group 1 (260 days vs. 144 days, p<.01); the proportion of women visiting a psychiatrist was also higher in Group 1 (33.7% vs. 26.8%, p<.01). The mean total cost during pregnancy in Groups 1 and 2 were $2981.5 vs. $1842.9 (p<.01), respectively, and after pregnancy were $1761.2 vs. $1024.9 (p<.01), respectively. When prescription costs were excluded, these differences in costs were no longer significant.
Conclusions
Women who use antidepressants during pregnancy are likely to have disorders of greater severity compared to those who discontinue during the first trimester. They incur significantly greater healthcare costs. However, this increased cost is attributable to higher prescription costs
References
2. Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 2006;295:499507.
3. Zuckerman B, Amaro H, Bauchner H, et al. Depressive symptoms during pregnancy: relationship to poor health behaviors. Am J Obstet Gynecol 1989;160:1107-1111.
4. Steer RA, Scholl TO, Hediger ML, et al. Selfreported depression and negative pregnancy outcomes. J Clin Epidemiol 1992;45:1093-1099.
5. Dominguez RA, Goodnick PJ. Adverse events after the abrupt discontinuation of paroxetine. Pharmacotherapy 1995;15:778-780.
6. Heron J, O'Connor TG, Evans J, et al. The course of anxiety and depression through pregnancy and the postpartum in a community sample. J Affect Disord 2004;80:65-73.
7. World Health Organization (WHO). International Classification of Diseases, Ninth revision. Geneva; 1997.
8. Régie de l'assurance maladie du Québec. Statistiques annuelles. Québec: RAMQ: Gouvernement du Québec; 1997.
9. Tamblyn R, Lavoie G, Petrella L, et al. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 1995;48:999-1009.
10. Levy AR, Mayo NE, Grimard G. Rates of transcervical and pertrochanteric hip fractures in the province of Quebec, Canada, 1981-1992. Am J Epidemiol 1995;142:428-436.
11. Berard A, Ramos E, Rey E, et al. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol 2007;80:18-27.
12. Blais L, Beauchesne MF, Rey E, et al. Use of inhaled corticosteroids during the first trimester of pregnancy and the risk of congenital malformations among women with asthma. Thorax 2007;62:320-328.
13. Ramos E, Oraichi D, Rey E, et al. Prevalence and predictors of antidepressant use in a cohort of pregnant women. BJOG 2007;114:10551064.
14. Ofori B, Rey E, Berard A. Risk of congenital anomalies in pregnant users of statin drugs. Br J Clin Pharmacol 2007;64:496-509.
15. Martel MJ, Rey E, Beauchesne MF, et al. Use of inhaled corticosteroids during pregnancy and risk of pregnancy induced hypertension: nested case-control study. BMJ 2005;330:230.
16. Rapport financier et statistique annuel. Système Opérationnel et Financier Informatisé (SOFI); 1997 - 2004.
17. Haukoos JS, Lewis RJ. Advanced statistics: bootstrapping confidence intervals for statistics with "difficult" distributions. Acad Emerg Med 2005;12:360-365.
18. Barber J, Thompson S. Multiple regression of cost data: use of generalised linear models. J Health Serv Res Policy 2004;9:197-204.
19. Dunn G, Mirandola M, Amaddeo F, et al. Describing, explaining or predicting mental health care costs: a guide to regression models. Methodological review. Br J Psychiatry 2003;183:398-404.
20. Bérard A, Lacasse-Morris A. External validity of perinatal pharmacoepidemiologic studies using data from the RAMQ administrative database. Soumis au Pharmacoepidemiology & Drug Safety 2008.
21. Blough DK, Ramsey SD. Using Generalized Linear Models to Assess Medical Care Costs. Health Services & outcomes research methodology. 2000;1:185-202.
22. Briggs A, Gray A. The distribution of health care costs and their statistical analysis for economic evaluation. J Health Serv Res Policy 1998;3:233-245.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.